SUNPHARMA.NS Sun Pharmaceutical Industries Limited
INR·Price 1802.40·Mkt cap 4.32TComputed from the latest reported financials and the current market price.
Who's the real player?
A genuine play on this theme — most of its business sits right here.
Is the business healthy?
A mixed picture — real strengths, but soft spots in cash flow, returns or debt.
- Strong cash flow quality
- High FCF conversion
- Low accrual ratio
- Solid margins
- Strong balance sheet
Are the smart people buying?
No ownership-change data for this stock. The score reflects heavy growth investment (capex) and buybacks, not visible insider buying.
- High founder/insider ownership
- Strong capex growth
- Active buybacks
What is management saying?
No earnings-call transcript or filings found for this stock.
Is the price right?
Intrinsic value 1348.85 vs price 1802.40 — screens expensive on a cash-flow DCF (-25.2% to intrinsic). The base FCF growth assumption of 15% is high and may not be sustainable long-term.
| Intrinsic / share | 1348.85 |
| Price | 1802.40 |
| Upside to intrinsic | -25.2% |
| Reverse-DCF implied g | 19.0% |
Base FCF 102.29B · growth 15.0% · discount 12.0% · terminal 5.0%.
Sensitivity — intrinsic value / share
Each cell is the intrinsic value at that growth (across →) and discount rate (down ↓). Center ★ is the base case. Cells green = above price (cheap), red = below (expensive).
| Growth rate → | |||||
|---|---|---|---|---|---|
| Disc ↓ ╲ g | 11% | 13% | 15% | 17% | 19% |
| 10% | 1449.73 | 1688.92 | 1966.67 | 2288.57 | 2660.96 |
| 11% | 1193.81 | 1384.3 | 1605.05 | 1860.45 | 2155.4 |
| 12% | 1011.99 | 1168.19 | ★ 1348.85 | 1557.49 | 1798.04 |
| 13% | 876.42 | 1007.3 | 1158.39 | 1332.56 | 1533.04 |
| 14% | 771.62 | 883.15 | 1011.64 | 1159.5 | 1329.41 |
Through the masters' eyes
Each investor's numeric rules, checked against this stock's metrics: exact math, no guesswork. Tap one to see which rules pass, fail, and what to judge yourself.
▶
Passes 2 of 2 of Peter Lynch's numeric checks. Still judge the non-numeric criteria below for yourself.
- Manageable debt (D/E ≤ 1.0) — now 0.06
- Solid liquidity (current ratio ≥ 1.5) — now 2.82
- A simple business you understand
- Which 'type' it is (fast grower, stalwart, cyclical…)
- A believable growth story
Couldn't check from available data: PEG ≤ 1 (growth cheap vs price) — not available; Earnings growth ≥ 15% — not available
▶
Passes 3 of 4 of Radhakishan Damani's numeric checks. Still judge the non-numeric criteria below for yourself.
- Very low debt (D/E ≤ 0.5) — now 0.06
- Consistent revenue (consistency ≥ 80%) — now 98.8%
- Positive net margin — now 19.7%
- High returns on capital (ROCE ≥ 18%) — now 15.7%
- A durable consumer franchise
- Pricing power
- A long runway, bought patiently
▶
Passes 2 of 3 of Rakesh Jhunjhunwala's numeric checks. Still judge the non-numeric criteria below for yourself.
- Net margin ≥ 10% — now 19.7%
- Conservative leverage (D/E ≤ 1.0) — now 0.06
- ROE ≥ 18% — now 13.7%
- A large, scalable opportunity
- Trustworthy, ambitious management
- Conviction to hold through volatility
Couldn't check from available data: Earnings growth ≥ 15% — not available
▶
Passes 3 of 5 of Warren Buffett's numeric checks. Still judge the non-numeric criteria below for yourself.
- Net margin ≥ 10% — now 19.7%
- Positive free cash flow — now 15.1%
- Conservative leverage (D/E ≤ 1.0) — now 0.06
- ROE ≥ 15% — now 13.7%
- Trades below intrinsic value (margin of safety ≥ 0) — now -33.6%
- A business you can understand
- A durable competitive moat
- Honest, capable management
▶
Passes 2 of 4 of Charlie Munger's numeric checks. Still judge the non-numeric criteria below for yourself.
- High returns on capital (ROCE ≥ 15%) — now 15.7%
- Conservative leverage (D/E ≤ 1.0) — now 0.06
- ROE ≥ 15% — now 13.7%
- Trades below intrinsic value (margin of safety ≥ 0) — now -33.6%
- A high-quality, understandable business
- A durable moat
- Management of integrity
▶
Passes 3 of 6 of Benjamin Graham's numeric checks. Still judge the non-numeric criteria below for yourself.
- Strong liquidity (current ratio ≥ 1.5) — now 2.82
- Debt below equity (D/E ≤ 1.0) — now 0.06
- Financially safe (Altman Z ≥ 3) — now 11.96
- P/E ≤ 15 — now 37.52
- P/B ≤ 1.5 — now 5.15
- Graham number: P/E × P/B ≤ 22.5 — now 193.2
- A long record of stable earnings
- An uninterrupted dividend history
▶
Passes 1 of 2 of Raamdeo Agrawal's numeric checks. Still judge the non-numeric criteria below for yourself.
- Longevity: revenue consistency ≥ 70% — now 98.8%
- Quality: ROCE ≥ 18% — now 15.7%
- Durability of the growth (longevity)
- Quality and honesty of management
Couldn't check from available data: Growth: earnings CAGR ≥ 15% — not available; Price: PEG ≤ 2 — not available
▶
Passes 1 of 2 of Vijay Kedia's numeric checks. Still judge the non-numeric criteria below for yourself.
- Manageable debt (D/E ≤ 1.0) — now 0.06
- ROE ≥ 15% — now 13.7%
- Ambitious, capable management
- A small company with a large opportunity
- Patience to hold for years
Couldn't check from available data: Strong earnings growth ≥ 20% — not available
Financial statements (INR)
↗ sourceCash-flow lines highlighted — we trust cash over reported profit.
| Line | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 582.20B | 520.41B | 477.58B | 432.79B | — |
| Operating income | 135.53B | 125.11B | 104.68B | 92.77B | — |
| EBITDA | 183.96B | 165.59B | 138.83B | 121.11B | — |
| Net income | 114.79B | 109.29B | 95.76B | 84.74B | — |
| Operating cash flow | 124.19B | 140.72B | 121.35B | 49.59B | — |
| Capex | -36.09B | -21.29B | -22.02B | -20.86B | — |
| Free cash flow | 88.10B | 119.44B | 99.33B | 28.74B | — |
| Total assets | 1.09T | 921.01B | 855.00B | 807.44B | — |
| Total equity | 835.70B | 722.18B | 636.67B | 559.95B | — |
| Total debt | 46.27B | 23.62B | 32.74B | 68.86B | — |
| Cash & equivalents | 97.71B | 102.69B | 92.86B | 46.24B | — |